Incyte To Acquire Escient And Its Assets For $750M Plus Escient's Net Cash Remaining At The Close Of The Transaction, Subject To Customary Adjustments
Incyte To Acquire Escient And Its Assets For $750M Plus Escient's Net Cash Remaining At The Close Of The Transaction, Subject To Customary Adjustments
Incyte (NASDAQ:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a definitive agreement under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist.
Incyte（納斯達克股票代碼：INCY）和推進全身免疫和神經免疫疾病新型小分子療法的臨床階段藥物發現和開發公司Escient Pharmicals已簽訂最終協議，根據該協議，Incyte同意收購Escient，包括MAS相關G蛋白偶聯受體X2（MRGPRX2）的同類首創、強效、高選擇性、每日一次的小分子拮抗劑 EP547，同類首創的口服 MRGPRX4 拮抗劑。EP262
Under the terms of the agreement, Incyte will acquire Escient and its assets for $750 million plus Escient's net cash remaining at the close of the transaction, subject to customary adjustments. The acquisition is subject to clearance under the Hart-Scott-Rodino Act, among other customary conditions, and will become effective promptly following the satisfaction or waiver of these conditions which is currently anticipated to be by the third quarter of 2024.
根據協議條款，Incyte將以7.5億美元的價格收購Escient及其資產，外加Escient在交易結束時剩餘的淨現金，但須視慣例調整而定。此次收購須經哈特-斯科特-羅迪諾法案及其他慣例條件的批准，並將在這些條件得到滿足或豁免後立即生效，目前預計將於2024年第三季度生效。
譯文內容由第三人軟體翻譯。